Senexis
Manchester, Manchester, United Kingdom
About Senexis
Senexis is operates as a small-molecule drug discovery company, engages in discovering compounds for the treatment of ageing-related diseases resulting from the toxicity of amyloid-like proteins. The company offers small molecule inhibitors of amyloid aggregation and toxicity as therapeutic agents to inhibit the pathogenic process of protein misfolding, amyloid-related toxicity, and inflammation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $8.0M
- Last round: Series Unknown (Jan 2008)
- Website: senexis.com
- Phone: +44 1223 496 160
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/senexis-2516112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.